Melatonin in cancer biology: pathways, derivatives, and the promise of targeted delivery

Drug Metab Rev. 2024 Feb;56(1):62-79. doi: 10.1080/03602532.2024.2305764. Epub 2024 Jan 30.ABSTRACTMelatonin, historically recognized for its primary role in regulating circadian rhythms, has expanded its influence particularly due to its wide range of biological activities. It has firmly established itself in cancer research. To highlight its versatility, we delved into how melatonin interacts with key signaling pathways, such as the Wnt/β-Catenin, PI3K, and NF-κB pathways, which play foundational roles in tumor development and progression. Notably, melatonin can intricately modulate these pathways, potentially affecting various cellular functions such as apoptosis, metastasis, and immunity. Additionally, a comprehensive review of current clinical studies provides a dual perspective. These studies confirm melatonin's potential in cancer management but also underscore its inherent limitations, particularly its limited bioavailability, which often relegates it to a supplementary role in treatments. Despite this limitation, there is an ongoing quest for innovative solutions and current advancements include the development of melatonin derivatives and cutting-edge delivery systems. By synthesizing the past, present, and future, this review provides a detailed overview of melatonin's evolving role in oncology, positioning it as a potential cornerstone in future cancer therapeutics.PMID:38226647 | DOI:10.1080/03602532.2024.2305764
Source: Drug Metabolism Reviews - Category: Drugs & Pharmacology Authors: Source Type: research